Breast Cancer | Specialty

Dr. Harismendy on the Challenges Faced With Molecular Testing in DCIS

January 25th 2021

Olivier Harismendy, PhD, discusses the challenge of molecular testing in patients with ductal carcinoma in situ.

Big Data Tool Finds Variations in Treatment and Costs Across 3 Cancer Types

January 25th 2021

Using real-world data from more than 4000 patients with common cancers, an algorithm was able to detect variations in care that, if reduced, could result in a median savings of $26,773 per patient.

Rugo Sets the Stage for a Busy Year in Breast Cancer

January 25th 2021

Hope S. Rugo, MD, FASCO, describes her work in medical oncology, previews the upcoming Miami Breast Cancer Conference, and speaks to what she is looking forward to in 2021 with regard to breast cancer treatment.

Updated Data for Metastatic HER2+ Breast Cancer

January 25th 2021

Prognostic Tools for Early-Stage HER2+ Breast Cancer

January 25th 2021

Current Treatment Landscape for HER2+ Breast Cancer

January 25th 2021

Hurvitz Highlights Key Developments Made in Metastatic HER2+ Breast Cancer Paradigm

January 23rd 2021

Sara A. Hurvitz, MD, reflects on key pivotal trials and recent regulatory decisions that have propelled progress in metastatic HER2-positive breast cancer.

Dr. Hamilton on the Rationale Behind OP-1250 in HR+ Metastatic Breast Cancer

January 21st 2021

Erika P. Hamilton, MD, discusses the rationale behind examining OP-1250 in patients with hormone receptor (HR)–positive, HER2-negative breast cancer.

Dr. Mittendorf on QoL With Neoadjuvant Atezolizumab/Chemo in Early TNBC

January 21st 2021

Elizabeth A. Mittendorf, MD, PhD, discusses patient-reported quality of life associated with neoadjuvant atezolizumab plus chemotherapy in early triple-negative breast cancer.

Forecasting Future Advances Across Oncology

January 21st 2021

Expert discuss their expectations for research and drug development in oncology in the new year.

Trastuzumab Deruxtecan Approved in Europe for HER2+ Metastatic Breast Cancer

January 20th 2021

January 20, 2021 - The antibody-drug conjugate trastuzumab deruxtecan has been granted conditional approval in the European Union for use as a single agent in the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received 2 or more HER2-based regimens.

Adjuvant Systemic Therapy Decision Factors

January 20th 2021

HR-/HER2+ Early Stage Breast Cancer: Standards of Care

January 20th 2021

FDA Grants Premarket Approval to Diagnostic Breast Cancer Imaging Technology

January 19th 2021

January 19, 2021 - The FDA’s Center for Devices and Radiological Health has granted premarket approval to diagnostic breast cancer imaging technology developed by Seno Medical Instruments to assist in the differentiation between benign and malignant breast lesions in patients.

Assessing Response to Chemotherapy in Metastatic Breast Cancer

January 19th 2021

Cytotoxic Chemotherapy for Metastatic Breast Cancer

January 19th 2021

Long-Term Disease Control in Metastatic Breast Cancer

January 19th 2021

Treatment Advances in Metastatic Breast Cancer

January 19th 2021

Dr. Tolaney on the Need to Develop Additional Biomarkers in mTNBC

January 14th 2021

Sara M. Tolaney, MD, MPH, discusses the need to develop additional biomarkers of response in metastatic triple-negative breast cancer.

Therapeutic Considerations in Metastatic HER2+ Breast Cancer: Part 2

January 14th 2021